Wichtige Dokumente

Gesamtdokumentation anzeigen

Fortfahren mit

R3530

Rifabutin

Name: Rifabutin
Brand: SIGMA

>98% (HPLC), powder, antibiotic

Synonym(e):

Ansatipin (Farmitalia), LM-427, Mycobutin (Farmitalia)

Anmelden zur Ansicht der Organisations- und Vertragspreise.

Größe auswählen

Ansicht ändern

Packungsgröße	SKU	Verfügbarkeit	Preis

Über diesen Artikel

Empirische Formel (Hill-System):

C₄₆H₆₂N₄O₁₁

CAS-Nummer:

72559-06-9

Molekulargewicht:

847.00

UNSPSC Code:

12352200

NACRES:

NA.77

Assay:

>98% (HPLC)

Form:

powder

Quality level:

100

Storage condition:

protect from light

Preise und Verfügbarkeit sind derzeit nicht verfügbar.

Technischer Dienst

Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.

Unterstützung erhalten

Produktname

Rifabutin, >98% (HPLC), powder

Quality Level

100

assay

>98% (HPLC)

form

powder

storage condition

protect from light

solubility

DMSO: >5 mg/mL

antibiotic activity spectrum

neoplastics

mode of action

enzyme | inhibits

originator

Johnson & Johnson

shipped in

wet ice

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Ähnliche Artikel vergleichen

Vollständigen Vergleich anzeigen

Unterschiede anzeigen

1 of 1

Dieser Artikel	1603800	Y0000149	SML2065
Sigma-Aldrich R3530 Rifabutin	USP 1603800 Rifabutin	Y0000149 Rifabutin	Sigma-Aldrich SML2065 Mequitazine
assay >98% (HPLC)	assay -	assay -	assay ≥98% (HPLC)
form powder	form -	form -	form powder
Quality Level 100	Quality Level -	Quality Level -	Quality Level -
storage temp. −20°C	storage temp. -	storage temp. 2-8°C	storage temp. −20°C
storage condition protect from light	storage condition -	storage condition -	storage condition desiccated
solubility DMSO: >5 mg/mL	solubility -	solubility -	solubility DMSO: 2 mg/mL, clear

Biochem/physiol Actions

Rifabutin is an antibiotic; antitumor.

Rifabutin is an antibiotic; antitumor. Rifabutin interferes with HSP-90 molecular chaperone, enhances ubiquitination and protein degradation, and inactivates bacterial RNA polymerase.

Features and Benefits

This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Lagerklasse

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Suche nach COA

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Helicobacter pylori eradication in Western Australia using novel quadruple therapy combinations.

C Y Tay et al.

Alimentary pharmacology & therapeutics, 36(11-12), 1076-1083 (2012-10-18)

Helicobacter pylori eradication rates with standard triple therapy are declining worldwide. The optimal management of H. pylori is evolving and new treatment combinations for antibiotic resistant H. pylori strains are required, especially for patients with penicillin allergy. To review the

Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects.

Kelly E Dooley et al.

Journal of acquired immune deficiency syndromes (1999), 62(1), 21-27 (2012-10-19)

Cotreatment of tuberculosis (TB) and HIV among coinfected patients is now the standard of care. Rifampin (RIF) is a standard part of TB treatment but is a potent inducer of drug metabolizing enzymes. This study evaluated the effect of RIF

The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment.

Jakko van Ingen et al.

American journal of respiratory and critical care medicine, 186(6), 559-565 (2012-06-30)

Currently recommended multidrug treatment regimens for Mycobacterium avium complex (MAC) lung disease yield limited cure rates. This results, in part, from incomplete understanding of the pharmacokinetics and pharmacodynamics of the drugs. To study pharmacokinetics, pharmacodynamics, and drug interactions of multidrug

Use of rifabutin for the treatment of a latent tuberculosis infection in a patient after solid organ transplantation.

Matthew D Hickey et al.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 19(4), 457-461 (2013-03-26)

Latent tuberculosis infection is an important problem for solid organ transplant recipients because of the frequency of its occurrence and its potential for reactivation. Because of the high mortality rate associated with active tuberculosis infections in transplant recipients, guidelines from

Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures.

J P Gisbert et al.

Alimentary pharmacology & therapeutics, 35(8), 941-947 (2012-03-01)

In some cases, Helicobacter pylori infection persists even after three eradication treatments. To evaluate the efficacy of an empirical fourth-line rescue regimen with rifabutin in patients with three eradication failures. Multicentre, prospective study. In whom the following three treatments had

Alle zugehörigen Dokumente anzeigen

Artikel

Bioactive Molecules for Immunology Research

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

Global Trade Item Number

SKU	GTIN
R3530-5MG	04061836695071
R3530-25MG	04061836695064

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung